Weekly News Round-up – 7/8/20
3 years ago
By Josh Neil
In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested pharma companies begin stockpiling drugs for the period immediately post-Brexit. In other news, more potential COVID drugs appear on the horizon, though the price for current candidates is seen to vary wildly between companies.
UK SIGNS COVID-19 VACCINE DEAL WITH GSK AND SANOFI – The UK government has signed a fourth deal on coronavirus vaccines, this time securing 60 million doses of an experimental treatment, The government also secured another 90 million doses of two other promising vaccines. The GSK/Sanofi vaccine is based on the recombinant protein-based technology Sanofi uses to produce a flu vaccine. Regulatory approval for the vaccine could be reached halfway through 2021, if all trials are successful.
UK GOVERNMENT CALLS FOR POST-BREXIT DRUG STOCKPILES – The UK government has requested that pharma companies stockpile at least six weeks’ worth of drugs in readiness for the full Brexit transition. This reserve would, it said, provide a buffer against the disruption caused by COVID-19.
U.S. GOVERNMENT SANOFI/GSK PAYS $2.1 BILLION FOR COVID VACCINE DOSES – The Trump administration has committed more than $2 billion for an initial 100 million doses of Sanofi/GSK’s potential COVID-19 vaccine. This comes as part of its Operation Warp Speed vaccine development initiative, and will accelerate manufacturing of the vaccine.
In other news:
R&D
Gilead urged to study potential COVID-19 treatment showing promise in cats
Clinical Trials
Eli Lilly’s COVID-19 antibody begins nursing home trials
Novavax COVID vaccine produces antibodies in early-stage trials
Manufacturing
Moderna and J&J have disclosed vastly different price points for their lead COVID-19 vaccine candidates
State attorneys request that U.S. lowers price of remdesivir
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Biomanufacturing Strategy Meeting 2020.
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years agoIntrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years ago